{"name":"Robbie Majzner","slug":"robbie-majzner","ticker":"","exchange":"","domain":"","description":"Robbie Majzner is a biotechnology company focused on developing innovative cell therapies for cancer. The company's lead product, B7-H3.CD28Z.CART, is currently in Phase 1 clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBsRHBEYWw4cmN2YUkzczRVekZlU0U4N0FLUlZHUWZ4a3hTMlRkUE1oTms1RWR4Yy1jNFhwdGdUb21vc1dwZ1JJY3pqUGJHbEJza3Rv?oc=5","date":"2025-12-16","type":"pipeline","source":"FirstWord Pharma","summary":"Backed by J&J and BMS, Link Cell debuts with logic-gated CAR-T playbook - FirstWord Pharma","headline":"Backed by J&J and BMS, Link Cell debuts with logic-gated CAR-T playbook","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPakZfX2F2WnhabTc2RTlpOG9GYlkybXpDWWxEbDRteVpDcVAwRk1PQ3dKVzhkcGJTTjhvXzM0MWVMNmhNaFBFZXZ5NlpzMFFWWTRyelFGenM5OUFZejNoNXoxbU90MDc3WlRZRXNyR3B2bnlJMjZOc3lJNWZIV1J5dGRTekZpSWh0T1hORjNGRFA3S2NxdlF2VE5ZNG1VSDBZaEZ1QlZR?oc=5","date":"2025-12-15","type":"pipeline","source":"The Pharma Letter","summary":"J&J leads $60 million Series A for newly-launched Link Cell - The Pharma Letter","headline":"J&J leads $60 million Series A for newly-launched Link Cell","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOSkFaQ1EwQjMyVWpfcUljRllZbnhhMzIyQklDOEVnRDRFdFNSQUNtZlhNZ0h1VWlBbE1uRHNZZTFTdjJ3c3dCeXJXVzBYeXYtaDJCTk9TU3pQdTlTa0Q0T29RR2d6XzE4UG00RjRIX3I5NlFnNHZfWWJaVzJyc2NDZ0J3UjZ0WkRJSXFscXhFdDVsTjhSOVBjOVA2cGpQU1QySzNZbQ?oc=5","date":"2025-12-15","type":"pipeline","source":"Fierce Biotech","summary":"J&J-backed Link launches with $60M, plan to create next-gen CAR-T therapies - Fierce Biotech","headline":"J&J-backed Link launches with $60M, plan to create next-gen CAR-T therapies","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}